Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,850 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Deformity; Skin Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

NCT00001373
View directory record Official record
Conditions
Familial Mediterranean Fever (FMF), Autoinflammation, Periodic Fever, Fever, Genetic Diseases, ROSAH, ALPK1
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Months to 115 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1994
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 7:38 PM EDT
Active, not recruiting Phase 2 Interventional

Vosoritide for Selected Genetic Causes of Short Stature

NCT04219007
View directory record Official record
Conditions
Short Stature
Interventions
Vosoritide
Drug
Lead sponsor
Andrew Dauber
Other
Eligibility
3 Years to 10 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 23, 2026, 7:38 PM EDT
Completed Phase 4 Interventional

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

NCT06806657
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Garadacimab
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Litchfield Park, Arizona • Bentonville, Arkansas • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 23, 2026, 7:38 PM EDT
Completed Phase 1 Interventional

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

NCT03556592
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Caffeine, Warfarin, Omeprazole, Metoprolol, Midazolam Hydrochloride
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 23, 2026, 7:38 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies

NCT04888936
View directory record Official record
Conditions
Costello Syndrome, Noonan Syndrome, Cardiofaciocutaneous Syndrome, Legius Syndrome, Capillary Arteriovenous Malformation Syndrome, RASopathy
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month to 99 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2035
U.S. locations
2
States / cities
Bethesda, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 7:38 PM EDT
Withdrawn No phase listed Observational

Effect of Laser Treatment on Capillary Malformations

NCT02035319
View directory record Official record
Conditions
Capillary Malformation, Port Wine Stain
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 23, 2026, 7:38 PM EDT
Recruiting Phase 2 Interventional

Cardamom and Topical Roseomonas in Atopic Dermatitis

NCT06096857
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Roseomonas mucosa (RSM2015) and Cardamom seeds, Placebo (sucrose)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 7:38 PM EDT
Suspended Not applicable Interventional

The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care

NCT04541381
View directory record Official record
Conditions
Gastrointestinal Cancer, Head and Neck Cancer, Dihydropyrimidine Dehydrogenase Deficiency, UGT1A1 Gene Mutation, Breast Cancer
Interventions
Availability of clinical decision support based on pharmacogenomic results.
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 23, 2026, 7:38 PM EDT
Completed Not applicable Interventional Results available

Prevention of Post Operative Bone Loss in Children

NCT00655681
View directory record Official record
Conditions
Osteoporosis, Cerebral Palsy, Spina Bifida, Osteopenia, Osteogenesis Imperfecta
Interventions
pamidronate, saline
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
4 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 23, 2026, 7:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With a Hybrid-Fractional Laser for Facial Rejuvenation

NCT06436261
View directory record Official record
Conditions
Photoaging, Wrinkle, Skin Laxity
Interventions
Hybrid Fractional Laser, Facial Cleanser, Facial Moisturizer, Sunscreen
Procedure · Other
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 23, 2026, 7:38 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

NCT03540160
View directory record Official record
Conditions
Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis
Interventions
5 mg Serlopitant Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
46
States / cities
Birmingham, Alabama • Fremont, California • North Hollywood, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 23, 2026, 7:38 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

NCT04739059
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
CSL312
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 23, 2026, 7:38 PM EDT
Completed No phase listed Observational

Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis

NCT00379678
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 23, 2026, 7:38 PM EDT
Completed Phase 3 Interventional

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT06343779
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema - Type 3, Hereditary Angioedema Type III
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
12 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 23, 2026, 7:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream

NCT02411162
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Combination therapy GSK2894512 Cream A + GSK2894512 Cream B, Combination therapy Vehicle Cream A + Vehicle Cream B
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 23, 2026, 7:38 PM EDT
Completed Not applicable Interventional

Restorative Eye Treatment and INhance in Upper Eyelid Blepharoplasty Surgery

NCT05007288
View directory record Official record
Conditions
Eyelid Dermatochalasis, Dermatochalasis
Interventions
Restorative Eye Treatment (RET) cream, INhance with Trihex Technology
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 23, 2026, 7:38 PM EDT
Completed Phase 2 Interventional

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

NCT05267262
View directory record Official record
Conditions
Alport Syndrome, Focal Segmental Glomerulosclerosis
Interventions
R3R01
Drug
Lead sponsor
River 3 Renal Corp.
Industry
Eligibility
12 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Los Angeles, California • Boca Raton, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 23, 2026, 7:38 PM EDT
Completed Not applicable Interventional

Brief Cognitive Behavioral Therapy to Treat Itch Rumination "Itch CBT" in Eczema

NCT04486742
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Itch CBT
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
8 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 23, 2026, 7:38 PM EDT
Completed Phase 1Phase 2 Interventional

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

NCT00237627
View directory record Official record
Conditions
Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
PS-341, Doxil, Velcade
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 23, 2026, 7:38 PM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

NCT07734415
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
Interventions
IMG-007
Drug
Lead sponsor
Inmagene LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
16
States / cities
Lancaster, California • Los Angeles, California • Ocala, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 23, 2026, 7:38 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis

NCT03054428
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin, Diseases Genetic, Genetic, Diseases Inborn, Skin, Disease, Eczematous Skin, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases, Dermatitis, Atopic
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 23, 2026, 7:38 PM EDT
Completed Not applicable Interventional

Text Messaging and Atopic Dermatitis

NCT01216059
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Text message to cell phone
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
10 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 23, 2026, 7:38 PM EDT
Not yet recruiting Phase 4 Interventional

Opzelura Experience Study

NCT07661979
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ruxolitinib, ruxolitinib and an Eczema Action Plan
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 23, 2026, 7:38 PM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

NCT01962415
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 23, 2026, 7:38 PM EDT